Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age19-50
SponsorDuke University
About this trial
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Eligibility criteria
Qualifiers
BRCA1 or BRCA2 germline mutation
scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
premenopausal
Disqualifiers
personal history of cancer
postmenopausal
>50 years old
unable to provide informed consent in English
Trial design
Treatments tested in this trial
- Experimental Arm
- SOC Arm
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov